Kodiak Sciences Inc (fra:K27) Share Price

Company Profile

Business description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Contact
1250 Page Mill Road
Palo AltoCA94304
USA
T: +1 650 281-0850
E: [email protected]
https://www.kodiak.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
124

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,047.30	25.90	-0.29%
CAC 40	8,421.14	46.84	-0.55%
DAX 40	24,985.82	40.98	-0.16%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,363.27	36.43	-0.35%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,250.06	196.57	0.28%
NZX 50 Index	13,535.25	39.62	0.29%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,828.70	27.90	-0.32%
SSE Composite Index	4,090.48	17.59	-0.43%